Compare Neurocrine Biosciences Inc (NBIX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

REMX, the VanEck Rare Earth and Strategic Metals ETF, trades at $77.52, down 1.19% today. The technical outlook is bullish based on moving averages, with a neutral oscillator reading. Recent news highlights U.S. efforts to build rare earth supply chain independence, with construction starting on Energy Fuels' Utah plant expansion (Forbes, 2026-08-04). The ETF provides exposure to 38 global rare earth companies but exhibits high volatility (~50% annualized) and turnover.

The long-term outlook for REMX is supported by geopolitical shifts and demand for critical minerals in technology and defense. However, risks include high volatility, China's dominance in the sector, and sensitivity to trade policies. Investors should weigh the growth potential against the ETF's speculative nature and lack of traditional fundamental metrics like P/E or P/S ratios.